(NasdaqGM:OKUR), — PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025 — Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with fulvestrant and ribociclib in HR+ metastatic breast cancer — […]
(NASDAQ:ICCC), PORTLAND, Maine, Aug. 12, 2025 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced it has successfully refinanced a portion of its bank debt.
(NASDAQ:SLS), – Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 –– Reported Positive Phase 2 Results of SLS009 in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) with Trial Meeting All Primary Endpoints; Full Data Presentation Expected Later This Year –– Alignment
(NASDAQ:DFDV), BOCA RATON, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) — https://www.youtube.com/@DeFiDevCorp DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today released its 2Q 2025 Shareholder Letter and Business Update. To read the full update, please visit:
(NASDAQ:VRNS), MIAMI, Aug. 12, 2025 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (Nasdaq: VRNS), the leader in data security, announced its participation at the following upcoming conference: Citi's 2025 Global TMT Conference, September 2 – 5, in New York. The presentation is scheduled for September 3 at 9:30 a.m. ET. The audio presentation will be webcast
(NYSE:HRB), – Delivered Revenue Growth of 4% and Earnings per Share Growth of 7% – – Returned $600 Million to Shareholders via Dividends and Share Repurchases – – Increases Quarterly Dividend by 12% – KANSAS CITY, Mo., Aug. 12, 2025 (GLOBE NEWSWIRE) — H&R Block, Inc. (NYSE: HRB) (the “Company”) today released financial results1 for
(NasdaqGM:ADAG), Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements. Company expects to begin enrolling patients in Phase 2 in 2H 2025 SAFEbody option exercised
(NASDAQ:PROP),(OTC US:CRKR),(Other OTC:CRKR),(OTC US:CRKRD),(Other OTC:CRKRD), Total Revenue of $68.1 million, an increase of approximately 400% quarter-over-quarter Net Income of $35.7 million, an increase of over 500% quarter-over-quarter Over 540% increase in quarterly production to a total of 21,052 Boe/d per day (50% oil) Record Adjusted EBITDA of $38.6 million, an increase of over 600% quarter-over-quarter
(NASDAQ:REKR), Improved Adjusted EBITDA: Substantially narrowed Adjusted EBITDA loss by $2 million for the six-month period. Operating Expense Reduction: Reduced operating expenses by 17% quarter over quarter and year over year, reflecting strong cost discipline. Quarterly Gross Revenue: Quarterly gross revenue of $12.4 million, showing the expected rebound from the prior quarter and resulting in
(NASDAQ:LYEL), Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphoma Initiated the PiNACLE pivotal trial of LYL314 in patients with large B-cell lymphoma receiving treatment in the thirdâ€' or later-line (3L+) setting; remain on track to initiate